What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Khavinson vascular tripeptide (Lys-Glu-Asp, KED)
Overview
Vesugen is a synthetic tripeptide with the sequence Lys-Glu-Asp (KED), developed by Vladimir Kh. Khavinson and the team at the St. Petersburg Institute of Bioregulation and Gerontology. It is also spelled "Vezugen" in some Khavinson-group literature and is referenced under the designation "T-38" in at least one paper. In Russia it is marketed as a "biologically active food supplement" (BAFS), not a registered pharmaceutical. It is positioned as a vascular bioregulator peptide targeting vascular endothelial aging. Published PubMed literature amounts to roughly a dozen to two dozen papers depending on search criteria (10-27 depending on how the search is scoped), consisting mostly of in vitro cell studies and rodent research. Only two small, uncontrolled human observational studies exist: one in vasculogenic erectile dysfunction (n=41, PMID 25051774) and one in elderly patients with multiple comorbidities and organic brain syndrome (n=32, PMID 26390612). Nearly all data originates from the Khavinson research group; no independent Western randomized controlled trial (RCT) has been published, and the proposed DNA-binding/docking mechanism has essentially not been independently replicated in Western laboratories. A 2021 mouse Alzheimer's study (PMID 34071923) received a published correction in January 2025 (PMID 39861198) — the correction addressed a figure-duplication formatting error between Figures 5 and 8, and the authors state the scientific conclusions are unaffected; this correction should be noted whenever citing that study. All core facts (molecular weight, formula, CAS number, sequence, sample sizes/designs of both human studies, and the correction notice) were independently re-confirmed in this third pass via direct PubChem API query and independent web searches, and match the conclusions of the two prior verification rounds with no new discrepancies found. Vialdyne releases Vesugen as a lyophilized tripeptide (linear) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Buyers for longevity-class peptides span research labs working on telomere, collagen, and circadian-rhythm models, plus cosmetic-formulation OEMs incorporating peptides like GHK-Cu into anti-aging finished products. Copper peptides in particular require attention to chelator-free water and EDTA-free buffers in downstream formulation work, incompatibility there is the most common cause of "the peptide didn't work" support tickets in this class.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Copper peptides require chelator-free water and EDTA-free buffers in downstream formulation work.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
A qualifying batch record for the KED tripeptide should carry an RP-HPLC purity result with the acceptance threshold stated, a mass-confirmation result consistent with the roughly 390 g/mol molecular weight, and an explicit Lys-Glu-Asp sequence assignment rather than mass alone. Because Vesugen shares the Khavinson naming space with the AEDx tetrapeptides, the sequence line matters for disambiguation. Also look for water content, counter-ion identity, and appearance of the lyophilizate. Acetate salt form and net-peptide versus gross-fill basis should be declared so reconstitution calculations start from the correct assay figure.
Supplier qualification pairs document review with independent confirmation. Treat the incoming COA as a starting claim, then run an in-house orthogonal check, typically a confirmatory HPLC retention comparison against a retained reference and a mass measurement, to verify the KED identity and the stated purity band. Compare the N-terminal-lysine charge behavior and retention against your reference profile, since that fingerprint separates Vesugen from the neutral-N-terminus tetrapeptides. Record lot number, assay basis, and re-test date, retain a sample, and require the sequence-verification data before releasing any lot into a research preparation workflow.
